INCY News and Press, Incyte Corporation From 04/17/23

2023-04-17 09:02:31 ET Summary With billions in revenues and modest growth, Incyte has an elephantine problem. Incyte is building a three pronged stool of therapies to generate revenues outside Jakafi. Its financial position is fully supportive of its efforts to bolster Jakafi...

- Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (Nasdaq: INCY) today anno...

2023-04-14 05:32:00 ET Ghana became the first country globally to approve a new malaria vaccine developed by the Oxford University, BBC reported. Ghana's Food and Drugs Authority approved the vaccine, dubbed R21, for use in children between five months to three years old. The Africa...

2023-04-13 05:02:47 ET A federal appeals court blocked part of a Texas court's ruling that would halt the access to the abortion pill mifepristone. Earlier this week, the U.S. Justice Department (DOJ) had asked the U.S. 5th Circuit Court of Appeals to halt U.S. Judge Matthew Kacsmar...

2023-04-05 11:58:46 ET MorphoSys AG ( NASDAQ: MOR ) added ~16% in the morning hours Wednesday after the German biotech indicated a faster-than-expected timeline for its ongoing late-stage study for experimental therapy, pelabresib, against blood cancer myelofibrosis. The com...

2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...

Incyte (Nasdaq:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre ® (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of myeloid/lymphoid neoplasms (MLNs) with FGFR1 fusion (also known...

2023-03-24 06:19:24 ET The U.S. Food and Drug Administration (FDA) declined to approve Incyte's ( NASDAQ: INCY ) ruxolitinib extended-release (XR) tablets to treat certain types of myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD). In its comple...

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD) use in the treatment of certain types of myelofibrosis (MF), polycythemia vera (PV)...

2023-03-22 14:09:27 ET Incyte ( NASDAQ: INCY ) announced Wednesday that the FDA cleared its intravenous PD-1 inhibitor Zynyz under the agency’s accelerated approval program for patients with Merkel cell carcinoma (MCC), a rare form of skin cancer. The agency has use...